Wragge & Co advises ProStrakan on cross-border agreement

Wragge & Co's Life Sciences team has advised ProStrakan Group plc on a cross-border licensing and distribution agreement with international pharmaceutical company Aptalis Pharma Inc.

Wragge & Co expands international presence with Dubai office

Wragge & Co has added a second office in the United Arab Emirates. In a move which highlights the importance of the Gulf region to the firm's international ambitions, Wragge & Co Legal Consultants LLC has opened in Dubai today, 6 September.

Wragge & Co wins 'best trainer' title at Training and Recruitment Awards

Wragge & Co has won the best trainer award in the national/large regional firm category at LawCareers.Net's Training and Recruitment Awards.

Wragge & Co advises Heptares Therapeutics on multi-million deal double

Wragge & Co's Life Sciences team has completed two deals in a week for biotechnology company Heptares Therapeutics.

Wragge & Co's IP team secures High Court victory for Lundbeck

Wragge & Co's Intellectual Property (IP) team has secured a winning High Court judgment for new client, global pharmaceutical company H. Lundbeck A/S in a patent dispute with Infosint.

Wragge & Co advises on £91 million life sciences deal

Wragge & Co's corporate experts have advised Astex Therapeutics on its proposed £91 million cross-border acquisition by NASDAQ-listed SuperGen Inc.

Wragge & Co boosts China office with director appointment

Wragge & Co has boosted its international credentials with the appointment of director Tom Carver from Howrey LLP. An experienced IP litigator, Tom will play an integral role in developing the firm's office in Guangzhou, China.

Wragge & Co secures cross-border agreement for Chroma Therapeutics

Wragge & Co's Life Sciences team has advised biotechnology company Chroma Therapeutics Ltd on a co-development and licensing agreement with biopharmaceutical company Cell Therapeutics Inc.

Wragge & Co advises Kennedy Research Institute on a new research centre to be created at the University of Oxford

Wragge & Co's Life Sciences team has advised the Mathilda and Terence Kennedy Institute of Rheumatology Trust (the KIR Trust) on a collaborative agreement with the University of Oxford to build a new rheumatology research centre on the Old Road campus at Oxford.

Wragge & Co enters Middle East legal market

Wragge & Co has entered the Middle East legal market. The full-service international law firm has joined forces with high-profile United Arab Emirates lawyer Mr Mohamed Al Mehairi to establish Wragge & Co Legal Consultants LLC in the UAE.

Wragge & Co advises Cambrex Corporation on cross-border acquisition

Wragge & Co's corporate experts have advised new client, NYSE-listed Cambrex Corporation, on acquiring a 51% stake in Indian pharmaceutical company Zenara for $20 million. The US-based life sciences company will acquire the remaining stake in early 2016 at a value to be determined.

Wragge & Co enhances IP practice with new partner hire

Wragge & Co has boosted its IP capability with the appointment of a new partner. Patent litigator and life sciences specialist Paul Inman joins the firm's London office from Howrey LLP, where he was an IP partner.

Wragge & Co advises Phoenix Pharmahandel on €3.6 billion refinancing

Wragge & Co has advised Germany's largest pharmaceutical wholesaler, Phoenix Pharmahandel, on the UK aspects of its €3.6 billion refinancing.

Wragge & Co in top five for innovation

Wragge & Co has been named one of the world's most innovative law firms in a Financial Times report. The firm is ranked in the top five in the FT's annual list of the 50 most innovative law firms.

Wragge & Co advises on cross-border life sciences M&A deal

Wragge & Co's Corporate group has advised new client Bioline group on its US $23.3 million (£15.2 million) cross-border acquisition by NASDAQ-listed Meridian Bioscience Inc.

Wragge & Co advises Astex on £300 million drug discovery alliance

Wragge & Co LLP's Life Sciences team has advised long-standing client Astex Therapeutics Limited on a £300 million drug discovery alliance with healthcare giant GlaxoSmithKline (GSK).

Wragge & Co advises Chroma Therapeutics on billion dollar deal double

Wragge & Co LLP's cross-firm life sciences practice has advised biotechnology company Chroma Therapeutics Limited on two simultaneous transactions completed in one day.

Wragge & Co advises Eisai on cross-border €95 million epilepsy deal

Wragge & Co LLP Life Sciences team has advised Eisai Europe Limited on a cross-border €95 million licence and co-promotion agreement with Bial-Portela & CA, S.A for the treatment for epilepsy.

Wragge & Co advises on cross-border outsourcing deal

Wragge & Co LLP IT team has advised new client Astellas Pharma Europe Ltd. on a pan-European outsourcing agreement.

Wragge & Co Life Sciences team advises Astex on $500 million drug discovery alliance

Wragge & Co LLP Life Sciences team has advised Astex Therapeutics Limited on a landmark $500 million drug discovery alliance with Janssen Pharmaceutica N.V.

Regulatory specialist joins Wragge & Co's Life Sciences team

Wragge & Co LLP has boosted its Life Sciences practice with a new regulatory specialist. Liz Fuller joins as director, life sciences regulatory (US qualified), bringing expertise in pharmaceutical and biotech regulatory affairs.

Wragge & Co's Life Sciences practice grows

Wragge & Co LLP has boosted its Life Sciences practice with the appointment of Dr Luke Kempton as a partner. With significant expertise in life sciences litigation, Luke will be a major force in driving forward the life sciences practice.

Wragge & Co appoints nine new partners

Wragge & Co LLP has appointed nine new partners, investing in key practice areas to deliver continued growth.

Wragge & Co advises Inverness Medical Innovations on UK public takeover

Wragge & Co advises AstraZeneca on collaboration with Silence Therapeutics

Wragge & Co LLP Life Sciences Team has advised AstraZeneca on its research and development collaboration with Silence Therapeutics to develop novel respiratory therapeutics.

Wragge & Co completes €41 million cross-border life sciences deal

Wragge & Co named IP law firm of the year